Quiet on the insider front: nobody at Arcadia Biosciences, Inc. bought or sold RKDA shares at market prices this past year.
Big money check: 16 institutions held RKDA as of Q2 2026, and funds were split between buying and selling. Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Feb 5, 2025 | Kawakami Mark | CFO | Buy | 700 | $2.49 | $2K | SEC |
| Feb 5, 2025 | Schaefer Thomas J. | CEO | Buy | 700 | $2.49 | $2K | SEC |
| Aug 20, 2024 | Kawakami Mark | CFO | Buy | 700 | $2.06 | $1K | SEC |
| Aug 20, 2024 | Schaefer Thomas J. | CEO | Buy | 700 | $2.06 | $1K | SEC |
| Feb 5, 2024 | Schaefer Thomas J. | CFO | Buy | 700 | $2.06 | $1K | SEC |
| Aug 7, 2023 | Schaefer Thomas J. | CFO | Buy | 649 | $3.67 | $2K | SEC |
| May 30, 2023 | Jacot Stanley Jr | CEO | Buy | 5,000 | $4.31 | $22K | SEC |
| Feb 2, 2023 | Schaefer Thomas J. | CFO | Buy | 700 | $0.23 | $161 | SEC |
There were no open-market insider trades in RKDA in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
16 investment managers reported holding RKDA in SEC Form 13F filings for Q2 2026.
No congressional trades in RKDA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).